Impact of COVID-19 on Inflammatory Bowel Disease Management

The COVID-19 pandemic has posed multifaceted challenges for the management of inflammatory bowel disease (IBD), affecting clinical decision-making, therapeutic strategies and patient well-being. Early in the pandemic, concerns over susceptibility to SARS-CoV-2 infection prompted a rapid reorganisation of service delivery, with elective procedures deferred and telemedicine adopted to maintain continuity of care. Immunosuppressive and biologic agents raised questions regarding infection risk and vaccine responsiveness; clinicians weighed the risks and benefits of corticosteroids, anti-TNF therapies and small-molecule inhibitors, often adapting dosing schedules or delaying infusions. Subsequent studies have clarified that while patients on certain agents may exhibit attenuated serological responses, appropriate booster regimens can mitigate this effect. In parallel, psychological burden and disease-related anxiety have emerged as important determinants of adherence and quality of life. Together, these developments have informed evolving guidelines that balance control of intestinal inflammation with minimising SARS-CoV-2 exposure and optimising immunisation strategies.

Research from Nature Portfolio

Immune responses to standard two-dose COVID-19 vaccination differ markedly between anti-TNF-treated and gut-selective integrin inhibitor-treated patients with IBD. Those receiving infliximab exhibit significantly lower peak anti-spike receptor-binding domain antibody concentrations and more rapid antibody decay than vedolizumab-treated counterparts. A proportion of anti-TNF recipients also fail to mount a detectable T-cell response. Breakthrough infections correlate inversely with antibody titre, emphasising the need for tailored booster schedules and monitoring of immunogenicity in high-risk subgroups.

Impact of COVID-19 on Inflammatory Bowel Disease Management publication trend

The graph below shows the total number of articles in impact of covid-19 on inflammatory bowel disease management across all publications each year (not limited to Nature Index journals).

Technical terms

Anti-TNF therapy: Treatment with monoclonal antibodies targeting tumour necrosis factor-α to reduce intestinal inflammation in IBD.

JAK inhibitor: Small-molecule drug that blocks Janus kinase signalling to modulate immune responses in inflammatory conditions.

Neutralising antibody titre: Concentration of antibodies capable of preventing viral entry into host cells, measured in serum.

Breakthrough infection: Occurrence of SARS-CoV-2 infection despite prior vaccination, often associated with lower antibody levels.

Cytokine storm: Exaggerated release of pro-inflammatory cytokines that can drive tissue damage in severe viral infections and inflammatory diseases.

References

1. Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study. EClinicalMedicine (2023).
2. Comprehensive analysis to identify the influences of SARS-CoV-2 infections to inflammatory bowel disease. Frontiers in Immunology (2023).
3. Anxiety and behavioral changes in Japanese patients with inflammatory bowel disease due to COVID-19 pandemic: a national survey. Journal of Gastroenterology (2023).
4. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nature Communications (2022).
5. Impact of COVID‐19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high‐volume Italian inflammatory bowel disease centre. United European Gastroenterology Journal (2020).
6. COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study. The Lancet Gastroenterology & Hepatology (2022).